Currently out of the existing stock ratings of Sean Laaman, 23 are a HOLD (34.85%), 40 are a BUY (60.61%), 3 are a SELL (4.55%).

Sean Laaman

Work Performance Price Targets & Ratings Chart

Analyst Sean Laaman, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 47.02% that have a potential upside of 21.42% achieved within 60 days.

Sean Laaman’s has documented 125 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EXEL, Exelixis at 23-Jul-2026.

Wall Street Analyst Sean Laaman

Analyst best performing recommendations are on RXRX (RECURSION PHARMACEUTICALS).
The best stock recommendation documented was for RMD (RESMED) at 4/25/2024. The price target of $207 was fulfilled within 1 day with a profit of $26.84 (14.9%) receiving and performance score of 148.98.

Average potential price target upside

of $58.47 (47.92%) on AXSM (AXSOME THERAPEUTICS).
of $23.9 (41%) on IRON (DISC MEDICINE).
of $21.92 (15.71%) on RMD (RESMED).

RMD ResMed EXEL Exelixis ARGX argenx NV ADR AXSM Axsome Therapeutics BMRN Biomarin Pharmaceutical CERT Certara HALO Halozyme Therapeutics RXRX Recursion Pharmaceuticals SDGR Schrodinger ABSI Absci Corp BBIO BridgeBio Pharma BGNE BeiGene Ltd CHE Chemed Corp DNLI Denali Therapeutics ERAS Erasca IRON Disc Medicine

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Craig Wong-Pan (RBC)